

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Pertuzumab with trastuzumab

INITIATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The individual has received an initial Special Authority approval for intravenous pertuzumab and trastuzumab for metastatic breast cancer
- and**
- Pertuzumab with trastuzumab to be administered subcutaneously at a maximum dose of 600 mg pertuzumab with 600 mg trastuzumab every three weeks (or equivalent)

or

- The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)

and

- Patient is chemotherapy treatment naïve
- or**
- Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer

and

- The patient has good performance status (ECOG grade 0-1)

and

- Loading dose of pertuzumab with trastuzumab to be administered subcutaneously at a maximum dose of 1200 mg pertuzumab with 600 mg trastuzumab, respectively

and

- Maintenance doses of pertuzumab with trastuzumab to be administered subcutaneously at a maximum dose of 600 mg pertuzumab with 600 mg trastuzumab every three weeks (or equivalent)

and

- Pertuzumab with trastuzumab to be discontinued at disease progression

CONTINUATION

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The individual has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)
- and**
- The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab

or

- Individual has previously discontinued treatment with pertuzumab with trastuzumab for reasons other than severe toxicity or disease progression

and

- Individual has signs of disease progression

and

- Disease has not progressed during previous treatment with pertuzumab with trastuzumab

I confirm that the above details are correct:

Signed: Date: